H.C. Wainwright analyst Joseph Pantginis raised the firm’s price target on Alpine Immune Sciences to $50 from $32 and keeps a Buy rating on the shares following the Q4 report. The analyst believes povetacicept has best in class potential, broad pharmaceutical applicability, and high market penetration.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALPN:
- Alpine Immune Sciences Highlights Key Communication Channels
- Options Volatility and Implied Earnings Moves Today, March 18, 2024
- Alpine Immune Sciences (ALPN) Q4 Earnings Cheat Sheet
- Alpine Immune Sciences price target raised to $41 from $29 at RBC Capital
- Alpine Immune Sciences assumed with an Outperform at Oppenheimer
